# A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

> **NCT06385678** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Advanced KRAS G12D Mutant Solid Tumors

## Interventions

- **DRUG:** HRS-4642
- **DRUG:** Adebrelimab
- **DRUG:** SHR-9839
- **DRUG:** Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection
- **DRUG:** Cetuximab Solution for Infusion

## Key facts

- **NCT ID:** NCT06385678
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-05
- **Primary completion:** 2025-12
- **Final completion:** 2026-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06385678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06385678, "A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06385678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*